<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.94085</article-id><article-id pub-id-type="publisher-id">ACM-30022</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190400000_48604374.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  吗啡联合普瑞巴林治疗伴焦虑、抑郁状态的癌性神经痛的临床研究
  Clinical Study of Morphine Combined with Prednisone in the Treatment of Carcinomatous Neuralgia with Anxiety and Depression
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>何</surname><given-names>建萍</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>包</surname><given-names>莉</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黄</surname><given-names>芳</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>燕</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>谭</surname><given-names>明英</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>四川大学华西医院门诊部，四川 成都</addr-line></aff><aff id="aff2"><addr-line>四川大学华西医院腹部肿瘤科，四川 成都</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>29</day><month>03</month><year>2019</year></pub-date><volume>09</volume><issue>04</issue><fpage>554</fpage><lpage>558</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：研究吗啡联合普瑞巴林治疗伴焦虑、抑郁状态的癌性神经病理性疼痛的疗效。方法：选取我院门诊及住院部癌性神经病理性疼痛伴焦虑、抑郁状态的患者各10例，分为AB两组，A组伴焦虑状态，B组伴抑郁状态。结果：AB两组的患者疼痛均有明显控制，两组焦虑、抑郁状态均有改善，且相关副作用能耐受。结论：吗啡联合普瑞巴林应用于伴有轻、中度焦虑、抑郁状态的中、重度癌性神经病理性疼痛患者是安全有效的。
    Objective: To study the effect of morphine combined with pregabalin in the treatment of malignant neuropathic pain with anxiety and depression state. Methods: 10 patients with malignant neuropathic pain accompanied by anxiety and depression state were divided into two groups: group A with anxiety state and group B with depression state. Results: Pain in both A B groups was significantly controlled; anxiety and depression state were improved in both groups, and the re-lated side effects were tolerable. Conclusion: Morphine combined with pregabalin is safe and ef-fective in patients with moderate to severe malignant neuropathic pain accompanied by mild to moderate anxiety and depression. 
  
 
</p></abstract><kwd-group><kwd>吗啡，普瑞巴林，癌性神经病理性疼痛，焦虑状态，抑郁状态, Morphine</kwd><kwd> Prebalin</kwd><kwd> Malignant Neuropathic Pain</kwd><kwd> Anxiety State</kwd><kwd> Depression State</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>吗啡联合普瑞巴林治疗伴焦虑、抑郁状态的癌性神经痛的临床研究<sup> </sup></title><p>何建萍<sup>1*</sup>，包莉<sup>2</sup>，黄芳<sup>2</sup>，李燕<sup>1</sup>，谭明英<sup>2</sup></p><p><sup>1</sup>四川大学华西医院腹部肿瘤科，四川 成都</p><p><sup>2</sup>四川大学华西医院门诊部，四川 成都</p><p><img src="//html.hanspub.org/file/28-1570787x1_hanspub.png" /></p><p>收稿日期：2019年4月8日；录用日期：2019年4月22日；发布日期：2019年4月29日</p><disp-formula id="hanspub.30022-formula46"><graphic xlink:href="//html.hanspub.org/file/28-1570787x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：研究吗啡联合普瑞巴林治疗伴焦虑、抑郁状态的癌性神经病理性疼痛的疗效。方法：选取我院门诊及住院部癌性神经病理性疼痛伴焦虑、抑郁状态的患者各10例，分为AB两组，A组伴焦虑状态，B组伴抑郁状态。结果：AB两组的患者疼痛均有明显控制，两组焦虑、抑郁状态均有改善，且相关副作用能耐受。结论：吗啡联合普瑞巴林应用于伴有轻、中度焦虑、抑郁状态的中、重度癌性神经病理性疼痛患者是安全有效的。</p><p>关键词 :吗啡，普瑞巴林，癌性神经病理性疼痛，焦虑状态，抑郁状态</p><disp-formula id="hanspub.30022-formula47"><graphic xlink:href="//html.hanspub.org/file/28-1570787x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/28-1570787x8_hanspub.png" /> <img src="//html.hanspub.org/file/28-1570787x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>癌痛发生率在癌症早期为48%，在晚期高达64%~75% [<xref ref-type="bibr" rid="hanspub.30022-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.30022-ref2">2</xref>] 。其中癌性神经痛(malignant neuropathic pain, MNP)是癌痛的重要类型，研究表明40%~60%癌痛患者有神经病理性疼痛 [<xref ref-type="bibr" rid="hanspub.30022-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.30022-ref4">4</xref>] ，国内学者研究报道，36.2%的癌症患者有神经病理性疼痛的症状，占癌痛患者的73.3%，严重影响患者的生活质量。癌痛患者中43.6%和33.3%有焦虑和抑郁 [<xref ref-type="bibr" rid="hanspub.30022-ref5">5</xref>] ，多项研究发现，癌症患者焦虑、抑郁情绪与躯体疼痛存在着显著正相关，疼痛引起焦虑、抑郁情绪，而情绪问题也会影响镇痛治疗的效果。本研究选取MNP伴焦虑、抑郁状态患者各10例，分组研究吗啡联合普瑞巴林治疗的效果。</p></sec><sec id="s4"><title>2. 资料与方法</title><sec id="s4_1"><title>2.1. 一般资料</title><p>选取2017年10月至2018年6月我院门诊、住院部MNP伴焦虑、抑郁状态的患者各10例，分成A、B两组，A组是MNP伴焦虑状态，B组是MNP伴抑郁状态。AB两组均符合《内科学》中MNP诊断标准。其中视觉模拟疼痛评分(VAS) ≥ 4分，焦虑自评量表(SAS)，中国常模50~59轻度焦虑，60~69中度焦虑，69以上为重度焦虑；抑郁自评量表(SDS)，按抑郁严重指数，0.5~0.59轻度抑郁，0.6~0.69中度抑郁，0.7以上为重度抑郁。排除近期使用过普瑞巴林或加巴喷丁药物者或其他抗焦虑、抑郁的药物者，排除重度焦虑、重度抑郁状态者。A组，男性6例，女性4例，年龄在42~68岁，肝癌4例，肠癌3例，宫颈癌1例，胰腺癌2例；中度疼痛(VAS 4~6) 4例，重度疼痛(VAS &gt; 7) 6例，轻度焦虑2例，中度焦虑8例；B组，男性5例，女性5例，年龄在34~68岁，肠癌5例，肝癌1例，胰腺癌2例，胃癌1例，膀胱癌1例，中度疼痛(VAS 4~6) 6例，重度疼痛(VAS &gt; 7) 4例，轻度抑郁4例，中度抑郁6例。</p></sec><sec id="s4_2"><title>2.2. 治疗方法</title><p>AB两组普瑞巴林均予以初始75 mg∙bid口服，逐渐加至150 mg∙bid，中度疼痛均初始予以盐酸吗啡缓释剂30 mg∙qn口服，重度疼痛根据患者需求使用盐酸吗啡缓释剂的剂量，AB两组从入组开始观察8周。</p></sec><sec id="s4_3"><title>2.3. 观察指标</title><p>治疗前后采用VAS、SAS、SDS量表评估两组患者疼痛、焦虑、抑郁程度，视觉模拟疼痛评分(VAS)，0~10分，0分无痛，1~3分轻疼痛，4~6分中度疼痛，&gt;7为重度疼痛；焦虑自评量表(SAS)，中国常模50~59为轻度焦虑，60~69为中度焦虑；抑郁自评量表(SDS)，按抑郁严重指数，0.5~0.59为轻度抑郁，0.6~0.69为中度抑郁。</p></sec></sec><sec id="s5"><title>3. 结果</title><p>VAS评分A组治疗前中度疼痛4例，重度疼痛6例，轻度焦虑2例，中度焦虑8例；B组，中度疼痛6例，重度疼痛4例，轻度抑郁4例，中度抑郁6例。治疗后A组疼痛完全缓解3例，显著有效5例，有所缓解1例，总缓解人数8例，B组完全缓解4例，显著缓解6例，总缓解人数10例，见表1；AB两组治疗前后SAS、SDS的评估，见表2，AB两组常见副作用，均在耐受范围，见表3。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> AB pain effects in both group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >N (例)</th><th align="center" valign="middle" >完全缓解</th><th align="center" valign="middle" >显著缓解</th><th align="center" valign="middle" >有所缓解</th><th align="center" valign="middle" >未缓解</th><th align="center" valign="middle" >总缓解</th></tr></thead><tr><td align="center" valign="middle" >A组</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >8</td></tr><tr><td align="center" valign="middle" >B组</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >10</td></tr></tbody></table></table-wrap><p>表1. AB两组疼痛效果</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The evaluation of SAS, SDS before and after treatment in both groups of A</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >无焦虑</th><th align="center" valign="middle" >轻度焦虑</th><th align="center" valign="middle" >中度焦虑</th><th align="center" valign="middle" >无抑郁</th><th align="center" valign="middle" >轻度抑郁</th><th align="center" valign="middle" >中度抑郁</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >治疗前</td><td align="center" valign="middle" >A组</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >B组</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >5</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >治疗后</td><td align="center" valign="middle" >A组</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >B组</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >7</td></tr></tbody></table></table-wrap><p>表2. AB两组治疗前后SAS，SDA评估</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Side effects of A</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >N (例)</th><th align="center" valign="middle" >恶心</th><th align="center" valign="middle" >呕吐</th><th align="center" valign="middle" >嗜睡</th><th align="center" valign="middle" >便秘</th><th align="center" valign="middle" >疲倦</th></tr></thead><tr><td align="center" valign="middle" >A组</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >B组</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2</td></tr></tbody></table></table-wrap><p>表3. AB两组副作用</p></sec><sec id="s6"><title>4. 讨论</title><p>据人类发展指数(Human Development Index, HDI)保守预测至2030年，每年将有2000万人被诊断为癌症。癌痛发生率在癌症早期为48%，在晚期高达64%~75% [<xref ref-type="bibr" rid="hanspub.30022-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.30022-ref2">2</xref>] 。其中癌性神经痛(malignant neuropathic pain, MNP)是癌痛的重要类型，研究表明40%~60%癌痛患者有神经病理性疼痛 [<xref ref-type="bibr" rid="hanspub.30022-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.30022-ref4">4</xref>] ，国内学者研究报道，36.2%的癌症患者有神经病理性疼痛的症状，占癌痛患者的73.3%，严重影响患者的生活质量。与伤害感受性疼痛相比其病因和机制更为复杂，神经病理性癌痛患者疼痛强度更大，疼痛频率更高，生活质量也更差。WHO三阶梯治疗后，仍然有45%的患者疼痛得不到控制，阿片类药物最常用于癌痛患者，但其对神经病理性疼痛的疗效不理想，因此，对于癌性神经病理性疼痛患者需联合使用辅助性镇痛措施 [<xref ref-type="bibr" rid="hanspub.30022-ref4">4</xref>] ，英国癌痛协会2010年发布的《癌痛的管理》提到：阿片类药物不再是治疗疼痛的唯一“神奇药物”，辅助药物与阿片类同样重要 [<xref ref-type="bibr" rid="hanspub.30022-ref6">6</xref>] ，如抗焦虑药、抗抑郁药和抗惊厥药。</p><p>癌痛患者中43.6%和33.3%有焦虑和抑郁 [<xref ref-type="bibr" rid="hanspub.30022-ref5">5</xref>] ，多项研究发现，癌症患者焦虑、抑郁情绪与躯体疼痛存在着显著正相关，疼痛引起的焦虑、抑郁情绪，而情绪问题会影响镇痛治疗的效果。患有焦虑、抑郁的患者在19个月内的死亡危险性是无焦虑、抑郁患者的2.6倍 [<xref ref-type="bibr" rid="hanspub.30022-ref7">7</xref>] 。但医生对癌症患者的焦虑、抑郁情绪识别率低，患者没有得到及时的干预及治疗而遭受着不必要的痛苦，不良的情绪严重影响癌症患者的生存质量，甚至影响癌症患者的免疫功能及肿瘤的发展、预后影响了癌症的治疗结局，并可增加医疗费用。由于疼痛和焦虑、抑郁情绪互为影响和互为加重，因此，在控制癌痛的同时，需要对癌症患者的情绪问题进行治疗。</p><p>普瑞巴林是一种α2-δ配体，是与电压门控钙离子通道相关的一种辅助蛋白，药物与此位点的牢固结合可导致神经末稍的钙离子内流减少，同时减少一些神经递质(谷氨酸，去甲肾上腺素、5-羟色胺、多巴胺及P物质)的释放 [<xref ref-type="bibr" rid="hanspub.30022-ref8">8</xref>] ，具有镇痛、抗焦虑及抗惊厥的活性，普瑞巴林已广泛应用于疼痛领域，可以快速有效地缓解疼痛，在欧盟被批准用于外周和中枢神经病理性疼痛，在FDA被批准为带状疱疹后神经痛、糖尿病周围神经痛、脊髓损伤后神经痛以及纤维肌痛综合征，是国内外指南共识推荐的神经病理性疼痛的一线用药和纤维肌痛综合征的A级推荐用药。并且普瑞巴林的安全性较好，不经肝脏代谢，不与血浆蛋白结合，几乎无药物相互作用，常见不良反应为头晕嗜睡，轻度到中度。在癌痛相关的指南 [<xref ref-type="bibr" rid="hanspub.30022-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.30022-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.30022-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.30022-ref12">12</xref>] 中被推荐为癌性神经痛的治疗用药。对于焦虑的治疗，2006年欧盟批准普瑞巴林用于广泛性焦虑，也是国际权威指南推荐的广泛性焦虑一线用药，普瑞巴林作用机制不同于其他的抗焦虑药物，相关研究和指南中指出 [<xref ref-type="bibr" rid="hanspub.30022-ref13">13</xref>] - [<xref ref-type="bibr" rid="hanspub.30022-ref18">18</xref>] ：普瑞巴林对广泛性焦虑障碍的精神和躯体症状均疗效确切，并且在治疗的前几天即可起效，相对于抗抑郁药，这是普瑞巴林的一大优势；我们临床观察吗啡联合普瑞巴林能有效缓解癌性神经病理性疼痛患者疼痛的程度、焦虑、抑郁状态，且毒副作用可以耐受，值得在临床中推广，由于我们观察人数少，在癌痛的治疗中仍有很多值得探索研究的内容。</p></sec><sec id="s7"><title>文章引用</title><p>何建萍,包 莉,黄 芳,李 燕,谭明英. 吗啡联合普瑞巴林治疗伴焦虑、抑郁状态的癌性神经痛的临床研究Clinical Study of Morphine Combined with Prednisone in the Treatment of Carcinomatous Neuralgia with Anxiety and Depression[J]. 临床医学进展, 2019, 09(04): 554-558. https://doi.org/10.12677/ACM.2019.94085</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.30022-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Van Den Beuken-Van Everdingen, M.H., et al. (2007) Prevalence of Pain in Patients with Cancer: A Systematic Review of the Past 40 Years. Annals of Oncology, 18, 1437-1449. &lt;br&gt;https://doi.org/10.1093/annonc/mdm056</mixed-citation></ref><ref id="hanspub.30022-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Hearn, J. and Higginson, I.J. (2003) Cancer Pain Epidemiology: A Systematic Review. In: Bruera, E.D. and Portenoy, R.K., Eds., Cancer Pain, Assessment and Management, Cambridge University Press, Cambridge, 19-37.  
&lt;br&gt;https://doi.org/10.1017/S0266466603004109</mixed-citation></ref><ref id="hanspub.30022-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bennett, M.I., Rayment, C., Hjermstad, M., et al. (2012) Prev-alence and Aetiology of Neuropathic Pain in Cancer Patients: A Systematic Review. Pain, 153, 359-365. &lt;br&gt;https://doi.org/10.1016/j.pain.2011.10.028</mixed-citation></ref><ref id="hanspub.30022-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">黄宇光, 等. 神经病理性疼痛临床诊疗学[J]. 北京: 人民卫生出版社, 2010: 439.</mixed-citation></ref><ref id="hanspub.30022-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">戴宇翃, 于世英. 癌痛患者焦虑抑郁的筛查及相关因素的初步调查[C]//中国抗癌协会. 第七届全国癌症康复与姑息医学大会大会论文集和专题讲座. 2011.</mixed-citation></ref><ref id="hanspub.30022-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">The British Pain Society (2010) Cancer Pain Management.</mixed-citation></ref><ref id="hanspub.30022-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Stommel, M., Given, B.A. and Given, C.W. (2002) Depression and Functional Status as Pre-dictors of Death among Cancer Patients. Cancer, 94, 2719-2727. &lt;br&gt;https://doi.org/10.1002/cncr.10533</mixed-citation></ref><ref id="hanspub.30022-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Fink, K., Dooley, D.J., Meder, W.P., et al. (2002) Inhibition of Neuronal Ca2+ Influx by Gabapentin and Pregabalin in the Human Neocortex. Neuropharmacology, 42, 229-236. &lt;br&gt;https://doi.org/10.1016/S0028-3908(01)00172-1</mixed-citation></ref><ref id="hanspub.30022-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">NCCN (2016) Clinical Practice Guidelines in Oncology: Adult Cancer Pain (Version 1).</mixed-citation></ref><ref id="hanspub.30022-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Virginie Piano, M.D., Verhagen, S., Schalkwijk, A., et al. (2014) Treatment for Neuropathic Pain in Patients with Cancer: Comparative Analysis of Recommendations in National Clinical Practice Guidelines from European Countries. Pain Practice, 14, 1-7. &lt;br&gt;https://doi.org/10.1111/papr.12036</mixed-citation></ref><ref id="hanspub.30022-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">卫生部 (2011) 癌症疼痛诊疗规范.</mixed-citation></ref><ref id="hanspub.30022-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">American Society of Clinical Oncology Clinical Practice Guideline (2016) Management of Chronic Pain in Survivors of Adult Cancers.</mixed-citation></ref><ref id="hanspub.30022-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Katzman, M.A., et al. (2014) Canadian Clinical Practice Guidelines for the Management of Anxiety, Posttraumatic Stress and Obsessive-Compulsive Disorders. BMC Psychiatry, 14, S1. &lt;br&gt;https://doi.org/10.1186/1471-244X-14-S1-S1</mixed-citation></ref><ref id="hanspub.30022-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Bandelow, B., et al. (2012) Guidelines for the Pharmacological Treatment of Anxiety Disorders, Obsessive-Compulsive Disorder and Posttraumatic Stress Disorder in Primary Care. International Journal of Psychiatry in Clinical Practice, 16, 77-84. &lt;br&gt;https://doi.org/10.3109/13651501.2012.667114</mixed-citation></ref><ref id="hanspub.30022-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Kasper, S., Herman, B., Nivoli, G., et al. (2009) Efficacy of Pregabalin and Venlafaxine-XR in Generalized Anxiety Disorder: Results of a Double-Blind, Placebo-Controlled 8-Week Trial. International Clinical Psychopharmacology, 24, 87-96. &lt;br&gt;https://doi.org/10.1097/YIC.0b013e32831d7980</mixed-citation></ref><ref id="hanspub.30022-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Lydiard, R.B. and Rickels, K. (2010) Comparative Efficacy of Pregabalin and Benzodiazepines in Treating the Psychic and Somatic Symptoms of Generalized Anxiety Disorder. International Journal of Neuropsychopharmacology, 90, 2441-2448.</mixed-citation></ref><ref id="hanspub.30022-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">汪庆玎, 吴鹏. 普瑞巴林联合阿片类药物治疗癌性神经病理性疼痛临床疗效观察[J]. 中国实用神经疾病杂志, 2017, 20(1): 89-91.</mixed-citation></ref><ref id="hanspub.30022-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">郑庆玲. 普瑞巴林在神经病理性癌痛患者中的应用[J]. 海南医学, 2018, 29(6): 843-844.</mixed-citation></ref></ref-list></back></article>